Role of ambulatory glucose profile in identifying and managing a patient with disparity between FPG, PPG and HbAlc levels: a case report

Banshi Saboo


This case report describes the management of a patient with mismatch/disparity between his Fasting Plasma Glucose (FPG)/ Postprandial Glucose (PPG) levels with that of Glycosylated Haemoglobin (HbA1c) levels. This 43-year-old male patient with Type 2 Diabetes Mellitus (T2DM) was presented with increased urination and tiredness, especially in the evening hours, along with a tingling sensation in bilateral feet on and off, with leg pain since past 4 months. The patient was obese with a family history of cardiovascular disease. In this patient, SGLT2 inhibitors were found to be effective in addressing glycaemic variability without triggering hypoglycaemic risk. Continuous glucose monitoring system aided in understanding the blood glucose fluctuations caused by the diet. This case study indicated that careful evaluation and appropriate management using Ambulatory Glucose profile would aid in preventing complications in such patients and improve the overall clinical outcomes.


Ambulatory glucose profile, Continuous glucose monitoring, Glycosylated haemoglobin, Type 2 diabetes mellitus

Full Text:



Little M, Humphries S, Patel K, Dewey C. Decoding the type 2 diabetes epidemic in rural India. Med Anthropol. 2017 Feb 17;36(2):96-110.

Unnikrishnan R, Anjana RM, Deepa M, Pradeepa R, Joshi SR, Bhansali A, et al. Glycemic control among individuals with self-reported diabetes in India-the ICMR-INDIAB study. Diabe Technol Therap. 2014 Sep 1;16(9):596-603.

Forum GP. Glycemic Pentad. J Assoc Phys Ind. 2017 Jul;65(7):68-79.

Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers!. Diabe Care. 2015 Aug 1;38(8):1615-21.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001 Dec;414(6865):813.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama. 2006 Apr 12;295(14):1681-7.

Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, Lou-Arnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabe Complicat. 2003 Mar 1;17(2):78-81.

Hsu CR, Chen YT, Sheu WH. Glycemic variability and diabetes retinopathy: a missing link. J Diabe Complicat. 2015 Mar 1;29(2):302-6.

Zoppini G, Verlato G, Targher G, Casati S, Gusson E, Biasi V, et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. Nutrit, Metab Cardiovas Dis. 2009 Jun 1;19(5):334-9.

Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?. Diab Metab. 2008 Dec 1;34(6):612-6.

Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diab Med. 2002 Oct;19(10):870-3.

Jin SM, Kim TH, Oh S, Baek J, Joung JY, Park SM, et al. Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring. Diab Med. 2015 Feb;32(2):274-9.

Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, De Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non–insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997 Sep 16;96(6):1750-4.

Smith-Palmer J, Brändle M, Trevisan R, Federici MO, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diab Res Clin Pract. 2014 Sep 1;105(3):273-84.

Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabe Metab. 2018 Sep 1;44(4):313-9.

Nalysnyk L, Hernandez‐Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabe, Obes Metab. 2010 Apr;12(4):288-98.

Krhač M, Lovrenčić MV. Update on biomarkers of glycemic control. World J Diab. 2019 Jan 15;10(1):1.

Chilelli NC, Burlina S, Sartore G, Lapolla A. Between reduction of glucose fluctuations and increased therapeutic adherence: an example of the benefits of vildagliptin in an elderly diabetic patient. Aging Clin Exper Res. 2015 Feb 1;27(1):85-7.

Nishimura R, Tanaka Y, Koiwai K, Inoue K, Hach T, Salsali A, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardio Diabetol. 2015 Dec;14(1):11.

Li FF, Gao G, Li Q, Zhu HH, Su XF, Wu JD, et al. Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J Diabe Res. 2016;2016.

Henry RR, Strange P, Zhou R, Pettus J, Shi L, Zhuplatov SB, et al. Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabe Technol Therap. 2018 Oct 25;20(11):715-24.

American Diabetes Association. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2019. Diabe Care. 2019 Jan;42(1):S71-S80.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019 Aug 31.